APEPTICO announces phase I trial with AP301 in oedematous respiratory failure pharmabiz.com AP301 is being developed for the prevention and treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation. The phase I single-centre clinical trial evaluated the safety, tolerability and ... |
